Research Reports

Key takeaways

FDA agreed a single-arm study with historical control could support resubmission of tab-cel BLA.

Pierre Fabre intends to submit updated dataset from ALLELE study with additional patients and longer follow-up.

Atara anticipates providing a further regulatory update in the third quarter.

The Type A meeting provided alignment on the regulatory framework for resubmission.

Atara's partner Pierre Fabre holds the BLA and controls the resubmission process.

Full analysis

Atara Biotherapeutics announced a productive Type A meeting with the FDA regarding the Complete Response Letter for tabelecleucel (tab-cel) BLA, held by partner Pierre Fabre. The FDA agreed that a single-arm study with an appropriate historical control could serve as adequate evidence for a future marketing application. Pierre Fabre plans to resubmit with an updated dataset from the ALLELE study, including additional patients and longer follow-up. This alignment reduces regulatory uncertainty and provides a clearer path to potential U.S. approval for tab-cel in EBV+ PTLD. Atara will continue to support Pierre Fabre and expects to provide another update in Q3 2026. The outcome is significant for Atara as it de-risks the regulatory pathway for its lead product candidate.

ATRA · Atara Biotherapeutics, Inc.

Summary

Key takeaways

Full analysis